Poly Medicure Limited (NSE:POLYMED)
India
· Delayed Price · Currency is INR | Market Cap | 153.18B |
| Revenue (ttm) | 17.82B |
| Net Income (ttm) | 3.48B |
| Shares Out | n/a |
| EPS (ttm) | 34.12 |
| PE Ratio | 44.06 |
| Forward PE | 39.94 |
| Dividend | 3.50 (0.23%) |
| Ex-Dividend Date | Sep 18, 2025 |
| Volume | 132,650 |
| Average Volume | 146,939 |
| Open | 1,493.60 |
| Previous Close | 1,495.60 |
| Day's Range | 1,478.00 - 1,529.90 |
| 52-Week Range | 1,182.00 - 2,937.60 |
| Beta | -0.08 |
| RSI | 58.61 |
| Earnings Date | May 7, 2026 |
About Poly Medicure
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous cat... [Read more]
Financial Performance
In fiscal year 2025, Poly Medicure's revenue was 16.70 billion, an increase of 21.37% compared to the previous year's 13.76 billion. Earnings were 3.39 billion, an increase of 31.09%.
Financial StatementsNews
Poly Medicure Transcript: Q3 25/26
Q3 FY26 saw 16.4% YoY revenue growth, strong gross margins, and robust domestic and international expansion, driven by acquisitions and new product launches. Guidance for FY27 targets 20%+ consolidated revenue growth, with continued margin strength and significant CapEx for capacity expansion.
Poly Medicure Ltd (BOM:531768) Q2 2026 Earnings Call Highlights: Strategic Acquisitions and ...
Poly Medicure Ltd (BOM:531768) Q2 2026 Earnings Call Highlights: Strategic Acquisitions and Domestic Growth Drive Performance
Q2 2026 Poly Medicure Ltd Earnings Call Transcript
Q2 2026 Poly Medicure Ltd Earnings Call Transcript
Poly Medicure Transcript: Q2 25/26
Q2 and H1 FY26 saw steady revenue and margin growth, with strong domestic performance and recovering international markets. Two European acquisitions are expected to boost annual revenue, while guidance for FY26 is revised to 15%-16% growth and 25%-27% EBITDA margin.
Poly Medicure Transcript: M&A Announcement
The acquisition secures a leading position in the orthopedic trauma and extremity market, with CTFE's strong product portfolio and direct sales presence in key geographies. The deal is valued at €31 million enterprise value, with significant growth and synergy potential, especially through portfolio expansion and leveraging global distribution.
Poly Medicure acquires Italy’s Citieffe for Rs 324 crore
Poly Medicure Ltd, one of India’s top medical device companies, has announced a major global expansion move. The company has signed a definitive agreement to acquire 100% stake in Medistream SA, which...
Poly Medicure Transcript: M&A Announcement
The acquisition of a European cardiology business supports global expansion, offering high-margin products, regulatory approvals, and significant synergy potential. Integration will consolidate operations, improve efficiency, and enable faster product launches in regulated markets.
Poly Medicure cuts FY26 export growth guidance to 5-10% from 15-18% earlier
Poly Medicure, a leading player in the medical devices sector, has recently updated its export growth forecast for the financial year 2025-26. The company has trimmed its earlier export growth guidanc...
Poly Medicure Transcript: Q1 25/26
Q1 FY26 saw 5% revenue growth, strong gross margins, and robust domestic expansion, while international business faced headwinds from tariffs and European market disruptions. Guidance for domestic growth remains at 30%, with international revised to 5%-10% and EBITDA margin at 25%-27%.
Poly Medicure Q1 Results: Revenue jumps 4.8% YoY to 403.21 crore, net profit up 25.8% YoY
Poly Medicure Limited posted steady growth in its consolidated earnings for the quarter ended June 30, 2025. Revenue from operations rose to ₹403.21 crore in Q1 FY26, a 4.8% increase from ₹384.78 cror...
Poly Medicure Transcript: Q4 24/25
Q4 and FY25 saw strong revenue and margin growth, with annual revenue up 21.5% and EBITDA margin at 27.1%. FY26 guidance targets 20% revenue growth, led by robust domestic and retail expansion, while export growth is conservatively guided amid global uncertainties.
Poly Medicure shares surge 3% as Q4 revenue rises 16.6% YoY to Rs 441 crore
Poly Medicure Ltd. witnessed a 3% surge in its share price during morning trade following the release of its robust Q4 results. The company reported impressive year-on-year growth across key financial...
Poly Medicure shares surge over 6% as Trump tariffs target Chinese medical imports; imposed 245% tariffs on syringes and needles
Shares of Poly Medicure Ltd jumped over 6% in Tuesday’s trade, rising Rs 122.40 to Rs 2,364.60, following a sharp rally triggered by escalating US-China trade tensions and renewed investor interest in...
Poly Medicure Ltd (BOM:531768) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Poly Medicure Ltd (BOM:531768) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Dialysis Challenges
Q3 2025 Poly Medicure Ltd Earnings Call Transcript
Q3 2025 Poly Medicure Ltd Earnings Call Transcript
Poly Medicure Transcript: Q3 24/25
Q3 FY25 saw 24.9% revenue growth and improved margins, with strong performance in infusion and renal segments. CapEx and new product launches are on track, and guidance for 20%+ growth and margin expansion remains intact. Exports and domestic business both contribute to robust outlook.
Poly Medicure Q3 FY25 Results: Revenue up 25% YoY to Rs 424 crore, net profit jump 31% YoY
Poly Medicure has reported a strong performance for its third quarter (Q3) earnings, showcasing impressive growth across key financial metrics. The company posted a net profit of ₹85 crore, marking a ...
Poly Medicure announces Joint Venture for solar power project
Poly Medicure Limited has entered into a joint venture agreement with AMPIN C&I Power Private Limited to establish a solar power project in Haryana, India. This initiative aims to supply power to Poly...
Top market losers today: ZF Commercial India plunges 12.85%, GE Vernova down 5.00%, Prestige Estates drops 3.59% in morning trade
In morning trade, at 9:58AM, the market witnessed significant losses across various sectors, with the following stocks leading the decliners: ZF Commercial India Ltd. tumbled 12.85% to ₹12,544.40, she...
Poly Medicure Transcript: Q2 24/25
Revenue grew 23% in H1 FY25, with EBITDA margin rising to 28.06% and PAT up to ₹87.22 crore. Export sales, especially to Europe, and domestic growth remain strong, while new capacity and QIP-funded expansion support future growth.
Poly Medicure Q2 Results: Revenue surges 9.15% YoY to ₹420.01 crore, Net Profit surges 40.64% YoY
Poly Medicure has reported robust financial results for Q2 FY24, showcasing significant growth both year-on-year (YoY) and quarter-on-quarter (QoQ). The company’s consolidated revenue and net profit f...
Stock market update: Q2 FY25 results today for Sumitomo Chemical, Pfizer, Poly Medicure, Firstsource, Anant Raj, CAMS, Kalpatru, Railtel and more
A variety of companies across the chemical, pharmaceutical, healthcare, technology, and infrastructure sectors are set to release their Q2 FY25 earnings results today. Investors and analysts will focu...
Top gainers in today’s market: Aptus surges 9.20%, BSE up 7.80%, Poly Medicure jumps 6.24%, CDSL rises 5.26%
As of 12:33 PM, the stock market witnessed notable movements with several companies leading the charge. Among the top gainers, Aptus Value Housing Finance, BSE Limited, and Poly Medicure emerged as st...
Poly Medicure shares rise nearly 2% after raising ₹1,000 crore through QIP
Poly Medicure Ltd. saw its shares rise nearly 2% after the company successfully raised ₹1,000 crore through a Qualified Institutional Placement (QIP). The institutional share sale was completed on Thu...
Stock to watch today: Poly Medicure launches QIP to raise ₹1,000 crore
Poly Medicure has initiated a Qualified Institutional Placement (QIP) aiming to raise ₹1,000 crore, according to CNBC-TV18. This move is set to result in a 5.54% equity dilution based on the company’s...